February 12, 2015 11:29 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Barclays on Thursday gave a Healthcare spotlight on Zoetis Inc. (NYSE: ZTS) after the biotech company reported fourth quarter earnings of $0.40 per share, beating analyst estimates of $0.37 EPS. Zoetis Inc also reported fourth quarter revenues of $1.32 billion, again beating consensus estimates of $1.275 billion. Barclays currently rates Zoetis Inc. as Equal Weight with a price target of $41. Douglas Tsao wrote that sales of its popular drug Apoquel were $34 million despite supply constraints. Management expects revenues for the drug to be between $150-175 million for the 2015 fiscal year due to increases in demand.Zoetis Inc. has shown "pipeline power" as the company recently submitted a filing to the USDA for a novel monoclonal antibody therapy along with a filing for Sarolaner, the active ingredient in their new flea/tick oral parasiticide. Shares of Zoetis Inc. have traded at $46.22, up 1 percent.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.